INES103 is an injectable recombinant humanized VHH (single variable domain of heavy chain, VHH)-Fc fusion protein against tumor associate macrophage（TAM）related target, to be administered for treatment of advanced or metastatic solid tumor and hematological malignancies. INES103 is designed to improve tissue penetration against solid tumors.
The efficacy of thatTAMrelatedtarget in solid tumors has not been well established yet. The poor penetration of monoclonal antibody due to its large molecular weight could be a factor. INES103 is rationally designed as VHH-Fc fusion protein. In addition to have better selectivity, it has a molecular weight (75 kd) only half of classical IgG antibody, potentially improving INES103 tumor penetration for better efficacy.
INES103 elicited potent antitumor effects against a broad range of solid tumors, especially when combination with other InxMed assets.